Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755103 | 0.94 | CYP19A1 (0.33) | CYP19A1FOLH1CYP1A1GPR88 | |
| SCHEMBL25755104 | 0.92 | CYP19A1 (0.33) | CYP19A1FOLH1CYP1A1GPR88 | |
| SCHEMBL25755107 | 0.91 | CYP19A1 (0.34) | CYP19A1FOLH1CYP1A1GPR88 | |
| SCHEMBL25755072 | 0.86 | DPP4 (0.39) | — | |
| SCHEMBL25755073 | 0.86 | CYP19A1 (0.34) | CYP19A1FOLH1CYP1A1GPR88HDAC1 | |
| SCHEMBL25755077 | 0.86 | FOLH1 (0.35) | CYP19A1FOLH1CYP1A1GPR88 | |
| SCHEMBL25754811 | 0.84 | SLC6A2 (0.34) | HDAC1 | |
| SCHEMBL25754814 | 0.84 | DPP4 (0.34) | — | |
| SCHEMBL25754849 | 0.82 | CYP19A1 (0.33) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL25755068 | 0.81 | PADI4 (0.34) | CYP19A1CYP1A1GPR88HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CYP19A1 2065/4885FOLH1 1055/4885CYP1A1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.